9,695,228 Shares in Alector, Inc. (NASDAQ:ALEC) Purchased by RA Capital Management L.P.

RA Capital Management L.P. purchased a new position in shares of Alector, Inc. (NASDAQ:ALEC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 9,695,228 shares of the company's stock, valued at approximately $18,324,000. RA Capital Management L.P. owned approximately 9.90% of Alector at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ALEC. JPMorgan Chase & Co. boosted its position in Alector by 64.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company's stock valued at $12,716,000 after acquiring an additional 1,072,298 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Alector by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,914,250 shares of the company's stock worth $3,619,000 after purchasing an additional 10,308 shares during the last quarter. Renaissance Technologies LLC boosted its position in Alector by 63.0% during the fourth quarter. Renaissance Technologies LLC now owns 915,738 shares of the company's stock valued at $1,731,000 after purchasing an additional 353,988 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Alector by 21.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 882,120 shares of the company's stock valued at $1,667,000 after purchasing an additional 157,231 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Alector by 5.6% in the fourth quarter. Northern Trust Corp now owns 759,874 shares of the company's stock valued at $1,436,000 after purchasing an additional 40,291 shares during the last quarter. Hedge funds and other institutional investors own 85.83% of the company's stock.

Alector Stock Up 6.6 %

Shares of Alector stock traded up $0.08 during midday trading on Friday, hitting $1.30. The company had a trading volume of 1,281,778 shares, compared to its average volume of 805,773. The company has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $2.23. The stock has a market cap of $128.81 million, a price-to-earnings ratio of -0.76 and a beta of 0.73. Alector, Inc. has a 12-month low of $0.87 and a 12-month high of $6.78.

Alector (NASDAQ:ALEC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.59. The business had revenue of $54.24 million during the quarter, compared to analysts' expectations of $20.41 million. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. As a group, analysts expect that Alector, Inc. will post -1.88 EPS for the current year.

Analyst Ratings Changes

ALEC has been the topic of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $7.00 price target on shares of Alector in a report on Thursday, February 27th. Morgan Stanley restated an "underweight" rating and issued a $1.50 target price (down from $3.00) on shares of Alector in a research note on Friday, March 7th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $3.50.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.